Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WTF does that have to do with it? The chart looks good.
El Nino Ventures 21,428,571-share private placement
2009-11-23 17:12 ET - Private Placement
The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced Oct. 16, 2009:
Number of shares: 21,428,571 shares
Purchase price: Seven cents per share
Warrants: 21,428,571 share purchase warrants to purchase 21,428,571 shares
Warrant exercise price: 15 cents for an 18-month period
Number of placees: 62 placees
Insiders: Protec Development Inc. (Michael Philpot), 285,714; John Royall, 142,857; Damian Towns, 142,857; Harry Barr, 185,714; Evolution Gold Resources Ltd. (Harry Barr), 495,714; Canadian Gravity Recovery Inc. (Harry Barr), 722,857; 293020 BC Ltd. (Harry Barr), 24,286
Pro group participation: Bill Whitehead, 650,000; Monty Sutton, 100,000; Len Cuthbert, 200,000; Michael Marosits, 100,000
Finders' fees: $875 cash payable to Alex Kuznecov; $43,651.65 cash payable to PI Financial Corp.; $1,960 cash payable to Global Securities Corp.; $3,500 cash payable to Mark Feene
Time to reload. Have you been keeping up with developments?
No mojo. They're scared to touch the puck for fear of giving it away and that's exactly what they do. Self fulfilling prophecy. They suck right now.
Ya right! lol
Very nice John.
You looking for something with torque? I thought that wasn't your style.
Kite surfer jumps over pier
Nope. Sold some GRI just before it broke out. lol
Canplats bought out
Canplats Resources Corporation (TSX VENTURE: CPQ) today announced an agreement whereby Goldcorp Inc. (TSX: G)(NYSE: GG) will acquire, through a plan of arrangement (the "Arrangement"), all of the outstanding common shares (the "Shares") of Canplats for total consideration of approximately C$238 million based on the fully diluted in-the-money Shares outstanding.
Under the Arrangement, each Share, including shares issued under the Arrangement on the acquisition by Goldcorp of the outstanding Canplats' options and warrants for their in-the-money value, will be exchanged for 0.074 of a common share of Goldcorp (the "Exchange Ratio") implying a price of approximately C$3.42 per Share based on the closing price of the Goldcorp shares on November 13, 2009. Shareholders will also receive a 90.1% interest in a new exploration company ("Newco") with a notional value of C
.18 per Share, representing a combined value of approximately C$3.60 per Share to Canplats' shareholders. This represents a premium of approximately 41% over the closing price of the Shares on Friday, November 13, 2009.
Upon closing, Goldcorp will assume ownership of Canplats' Camino Rojo Project, located approximately 50 kilometres southeast of Goldcorp's Penasquito mine. Camino Rojo's 3,389-square kilometre land position includes the Represa deposit, which has reported measured and indicated resources of 3,445,000 gold ounces and 60,708,000 silver ounces with inferred resources of 555,000 ounces of gold and 7,612,000 ounces of silver (see Table 1 to follow).
As part of the Arrangement, a new exploration company will be created and 90.1% of its shares will be distributed to Canplats' shareholders. Newco will hold cash in the amount of C$10 million and Canplats' existing interests in a number of precious and base metal projects located in Mexico, being the Rodeo and El Rincon properties, located in Durango, and the Mecatona, Maijoma and El Alamo properties, located in Chihuahua, through a newly-incorporated, wholly-owned Mexican subsidiary. All of the shares of Newco (other than a 9.9% equity interest to be retained by Goldcorp) will be distributed to Canplats' shareholders pursuant to the Arrangement.
"We are extremely pleased to have reached an agreement with one of the world's largest and most respected gold producers," said Gordon Davis, Canplats' CEO and Chairman. "The agreement provides our shareholders with immediate value and the prospect for future gains through a newly-incorporated company that will have C$10 million in the treasury, an exciting portfolio of precious and base metal projects in Mexico, and a significant and strategic shareholder, Goldcorp."
The acquisition of Canplats by Goldcorp is expected to be completed by way of a court approved plan of arrangement whereby each Share will be exchanged for 0.074 of a common share of Goldcorp and a fraction of a share of Newco. The number of Goldcorp shares to be issued will be approximately 4.3 million based on the issued and outstanding Shares as of the announcement date, but will be subject to adjustment depending on the aggregate in-the-money value of the Canplats' options and warrants at the time that the Arrangement is completed. The transaction is expected to close in January 2010. Closing of the transaction is subject to customary conditions, including approval by Canplats' security holders and the receipt of court and necessary regulatory approvals.
The Arrangement has been approved by the boards of directors of Goldcorp and Canplats and will be subject to, among other things, the favourable vote of 66 2/3% of the holders of Canplats' common shares, options and warrants voting as a single class at a special meeting of Canplats' security holders called to approve the transaction. Officers and directors of Canplats have entered into lock-up and support arrangements with Goldcorp under which they have agreed to vote in favour of the transaction, such shares, options and warrants, representing approximately 6.6% of Canplats' outstanding shares, options and warrants. Genuity Capital Markets, Canplats' financial advisor, and Salman Partners, the financial advisor to the special committee of the board of directors of Canplats (the "Special Committee"), have provided oral opinions to Canplats' board of directors and the Special Committee, respectively, that the consideration under the Arrangement is fair, from a financial point of view, to Canplats' shareholders.
In the event that the transaction is not completed, Canplats has agreed to pay Goldcorp a termination fee of C$7.2 million, under certain circumstances. Canplats has also provided Goldcorp with certain other customary rights, including a right to match competing offers.
Canplats' financial advisor is Genuity Capital Markets; its legal advisors are Lawson Lundell LLP in Canada and Skadden, Arps, Slate, Meagher & Flom LLP in the United States. The Special Committee's financial advisor is Salman Partners; its legal advisor is Blake, Cassels & Graydon LLP. Goldcorp's financial advisor is GMP Securities L.P.; its legal advisors are Cassels Brock & Blackwell LLP in Canada and Neal, Gerber & Eisenberg LLP in the United States.
Canplats' security holders and other interested parties are advised to read the materials relating to the proposed transaction that will be filed with or furnished to securities regulatory authorities in Canada and the United States when they become available because they will contain important information. Anyone may obtain copies of these documents when available free of charge under Canplats' profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and from the United States Securities and Exchange Commission at its website at www.sec.gov. This announcement is for informational purposes only and does not constitute an offer to purchase, a solicitation of an offer to sell the Shares or a solicitation of a proxy.
Table 1: Represa Deposit Mineral Resource Summary (i)(ii)
------------------------------------------------------------------------
Size Grade
----------------------------------- Gold Silver
Tonnes Gold Silver Zinc Lead Ounces Ounces
Category (Millions) (g/t) (g/t) (%) (%) (000's) (000's)
------------------------------------------------------------------------
Measured 9.58 0.76 13.40 0.34 0.29 235 4,126
------------------------------------------------------------------------
Indicated 153.81 0.65 11.44 0.37 0.18 3,210 56,582
------------------------------------------------------------------------
Total M&I 163.39 0.66 11.56 0.37 0.19 3,445 60,708
------------------------------------------------------------------------
Inferred 31.03 0.56 7.63 0.31 0.10 555 7,612
------------------------------------------------------------------------
(i) Based upon a cut-off grade of 0.2 grams gold per tonne for oxide
and transitional resources, with a cut-off grade of 0.3 grams gold
per tonne for sulphide resources.
(ii) Resources estimated by Mr. Douglas Blanchflower, P.Geo., of
Minorex Consulting, an independent qualified person under NI 43-101,
in a technical report dated January 5, 2009 and entitled "Technical
Report on the Mineral Resources of the Camino Rojo Property."
To receive Canplats' news releases by e-mail, contact Blaine Monaghan, Director, Investor Relations, at info@canplats.com or (866) 338-0047.
Statements contained in this news release that are not historical fact, such as statements regarding the economic prospects of the company's projects, future plans or future revenues, timing of development or potential expansion or improvements, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 and forward-looking information under the provisions of Canadian securities laws (collectively, "forward-looking statements"). Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from estimated results. Such risks and uncertainties include, but are not limited to, the company's ability to raise sufficient capital to fund development, changes in economic conditions or financial markets, changes in prices for the company's mineral products or increases in input costs, litigation, legislative, environmental and other judicial, regulatory, political and competitive developments in Mexico, technological and operational difficulties or inability to obtain permits encountered in connection with exploration and development activities, labour relations matters, and changing foreign exchange rates, all of which are described more fully in the company's filings with the Securities and Exchange Commission and on SEDAR. The Company undertakes no obligation to publicly update or otherwise revise any forward-looking statements, whether as a result of new information, future events or other factors, except as required by law. Readers are cautioned not to place undue reliance on forward-looking statements.
Cautionary note to U.S. investors: The terms "measured mineral resource", "indicated mineral resource", and "inferred mineral resource" used in this news release are Canadian geological and mining terms as defined in accordance with National Instrument 43-101, Standards of Disclosure for Mineral Projects ("NI 43-101") under the guidelines set out in the Canadian Institute of Mining, Metallurgy and Petroleum (the "CIM") Standards on Mineral Resources and Mineral Reserves. We advise U.S. investors that while such terms are recognized and permitted under Canadian regulations, the SEC does not recognize them. U.S. investors are cautioned not to assume that any part or all of the mineral deposits in the measured and indicated categories will ever be converted into reserves. "Inferred mineral resources" in particular have a great amount of uncertainty as to their economic feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Under Canadian rules estimates of inferred mineral resources may not generally form the basis of feasibility or other economic studies. U.S. investors are cautioned not to assume that any part or all of an inferred mineral resource exists, or is economically or legally mineable. Disclosure of contained metal expressed in ounces is in compliance with NI 43-101, but does not meet the requirements of Industry Guide 7 of the SEC, which will only accept the disclosure of tonnage and grade estimates for non-reserve mineralization. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Canplats Resources Corporation - Corporate Information
R.E. Gordon Davis
Chairman and C.E.O.
Direct: (604) 629-8292
Canplats Resources Corporation
Bruce A. Youngman
President and C.O.O.
Direct: (604) 629-8293
Canplats Resources Corporation - Investor Inquiries
Blaine Monaghan
Director, Investor Relations
Direct: (604) 629-8294 or Toll-Free: (866) 338-0047
info@canplats.com
www.canplats.com
G2 Consultants Corporation
NA Toll-Free: (866) 742-9990 or (604) 742-9990
(604) 742-9991 (FAX)
canplats@g2consultants.com
SOURCE: Canplats Resources Corporation
mailto:info@canplats.com http://www.canplats.com mailto:canplats@g2consultants.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Pure speculation. They have a compound which is effective in inhibiting growth in cancer cells as well as killing cancer cells. It is a peptide compound that specifically targets cancer cells. They company is in the final stages of pre-clinical and getting a lot of attention. Testing currently underway at OHRI (Ovarian cancer cell lines), Sloan Kettering (Melanoma), meetings this month with NCI (possible collaboration there). If the compound goes through the first stage of clinical and shows promise (of being non-toxic to healthy tissue) then I expect the company will be offered a licensing deal. A $100 million offer plus royalty wouldn't be out of the ordinary.
There's not much downside at .19 and a lot of upside.
The mother of all buying opportunities now on GAP.
BUY GAP NOW $1.00 a share in 12 months.
CLN
Moydow Mines International Inc. Enters into Agreement with Franco-Nevada Corporation Providing for the Acquisition of Moydow-Transaction Valued at US$58 Million
Last Update: 11/10/2009 10:07:38 AM
TORONTO, ONTARIO, Nov 10, 2009 (MARKETWIRE via COMTEX) -- Moydow Mines International, Inc. ("Moydow" or the "Company") (MOY) (AIM: MOY) today announces that it has entered into an agreement (the "Agreement") with Franco-Nevada Corporation (FNV) ("Franco-Nevada") which sets out the basis on which Franco-Nevada will acquire the Company and its 2% Net Smelter Returns royalty (the "Ntotoroso Royalty") on a portion of Newmont Mining Corporation's Ahafo gold mine in Ghana for total consideration valued at US$58 million.
The Company's President and Chief Executive Officer, Brian Kiernan commented: "We are very pleased to announce this agreement with Franco-Nevada. This is an excellent result for Moydow and its shareholders. The Ntotoroso Royalty is Moydow's principal asset and we believe that this is the right time to realize its value for our shareholders through its sale to Franco-Nevada. Franco-Nevada is one of the world's premier precious metals royalty companies. Through the sale of Moydow and the royalty to Franco-Nevada, we believe we offer our shareholders continued exposure to the Ntotoroso royalty as well as increased leverage to rising commodity prices from Franco-Nevada's broader portfolio of precious metals and oil and gas royalties.
The Agreement provides that Moydow and Franco-Nevada are to complete definitive transaction agreements, including the arrangement agreement and the partial royalty purchase agreement, by 5:00 pm (Toronto time) on November 20, 2009. The transaction will be carried out in two steps whereby Franco-Nevada will first purchase 20% of the Ntotoroso Royalty for cash consideration of US$13 million. Following receipt of approval by Moydow shareholders and satisfaction of other customary closing conditions, the parties will then carry out a court-approved plan of arrangement (the "Arrangement"), whereby Franco-Nevada will acquire all of the issued and outstanding common shares of Moydow ("MOY Shares") in exchange for common shares of Franco-Nevada ("FN Shares") on the basis of 0.02863 FN Shares for each MOY Share (the "Exchange Ratio"). Moydow will be delisted from the TSX and AIM and Moydow shareholders will receive FN Shares in exchange for their Moydow shares in accordance with the Exchange Ratio. The proposed transaction includes a number of related party transactions which will be fully disclosed to shareholders in the circular convening the Extraordinary General Meeting.
The Agreement may be terminated in certain circumstances, including if the parties do not enter into the definitive transaction agreements by the November 20th deadline or by Franco-Nevada as a result of its due diligence review of Moydow. Moydow has also agreed not to solicit alternative proposals and has agreed to pay a break fee to Franco-Nevada in certain circumstances if it enters into a superior proposal.
Certain shareholders of Moydow, including Brian Kiernan, holding approximately 55% of the outstanding MOY Shares, will enter into lock-up agreements pursuant to which they will agree to support and vote in favour of the Arrangement. The parties expect the transaction will close in January 2010.
The Company is engaged in the acquisition, exploration and development of mineral properties worldwide. Corporate information is available on the Company's website www.moydow.com . The Company is listed on the Toronto Stock Exchange and the AIM Market of the London Stock Exchange under the symbol "MOY."
On behalf of the Board of Directors
Brian Kiernan, President and Chief Executive Officer
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Generally, forward-looking statements can be identified by the use of the forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Assumptions upon which such forward-looking statements are based include that the conditions in the Framework Agreement and the definitive agreements will be satisfied, that Franco-Nevada will be satisfied with its due diligence investigation of Moydow, that the required approvals will be obtained from the shareholders of Moydow, that all third party regulatory and governmental approvals to the transaction described herein will be obtained and all other conditions to the completion of the transactions described herein will be satisfied or waived. Many of these assumptions are based on factors and events that are not within the control of Moydow and Franco-Nevada and there is no assurance they will prove to be correct. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Moydow and Franco-Nevada to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to mineral prices, market and industry expectations, the mining industry and general economic and political conditions, as well as those factors discussed in the section entitled "Description of the Business - Risk Factors" in Moydow's Annual Information Form for the year ended December 31, 2008 and although Moydow has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Moydow does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws.
Contacts:
Moydow Mines International, Inc.
Michael Power
Vice President, Corporate Development
416-703-3751
SOURCE: Moydow Mines International Inc.
Copyright 2009 Marketwire, Inc., All rights reserved.
ARCO'S MEXICAN EXPLORATION UPDATE
October 14, 2009 -- Vancouver, B.C.: Arco Resources Corp. (ARR: TSX-V) is pleased to announce that the Company is once again focused on its Oaxaca portfolio of mineral properties in southern Mexico. Arco Resources Corp. holds six perspective mineral properties in the mineral rich and historically productive state of Oaxaca. All of the properties are at the exploration stage, however, each has historic workings both pre and post Mexican revolution vintage. The properties are prospective for silver, gold and polymetallic mineralization.
The Company has begun selective sampling and data compilation campaigns to prioritize its subsequent efforts. The Company is also evaluating other undervalued acquisition opportunities in the Oaxaca state. The Company employs a competent and experienced crew of Mexican nationals based in the capital of Oaxaca, directed technically by the Company's new Chief Geologist, Paul Cowley, P.Geo.
About The Company Properties
Taviche
Taviche is an attractive silver-gold-bearing quartz vein with typical epithermal textures and existing historic (Spanish and subsequent) underground workings. The vein can be traced for over 1.5 kilometres. Five hundred metres of continuous underground workings can be seen in one level. A second deeper level is known to have a 100 metres length. The laterally continuous vein varies in thickness from 1-5 metres but appears to average 2 metres and is sub vertical. Epithermal textures include open space fillings, bladed veining and megacrystic carbonate replacement, all significant textures known in gold-silver epithermal deposits. There are no records of the grades from the vein system but one speculates that for the amount of labour and extraction on the vein, grades must have been significant. The Company plans on conducting an extensive underground re-sampling program to determine the average grade before considering a drill program. The access is excellent, less than 1 kilometre from paved road and approximately 1.5 hours drive from the capital of Oaxaca.
Lachiguiri (NI 43-101)
The 4,200 hectare Lachiguiri Property covers a large quartz-rich carbonate replacement alteration system focused on a silver-lead-zinc-bearing vein system. The alteration system covers a strike-length of at least 5 kilometre with thick multiple laterally extensive trends of quartz with strong epithermal textures. The trends of quartz appear to average 5-15 metres thick and textures observed are open space fillings, cockscomb, drussy quartz, bladed, veined and micro-veined, all typical of silver-gold epithermal deposits. The property is covered by thick jungle and outcrops are limited which has slowed exploration progress to evaluate the significance of the large alteration system. Previous work has focused on a 500 metre long part of the vein system where historic (Spanish and subsequent) underground exploration and extraction has taken place. Sampling from dumps has returned bonanza values at high as 1510 g/t silver. Chimneys of mineralization are documented to be 5-50 metres wide and 100-300 metres long. At least 2 steeply dipping mineralized shoots are evident and form obvious drill targets, however, the Company prefers to evaluate the larger alteration system by conducting an inexpensive broad based soil sampling program.
Quatro Venados
The 3,631 hectare Quatro Venados Property covers a 5 kilometre strikelength of a gold-bearing quartz vein. Historic mining took place in the northern and southern parts of the vein. The northern multi level underground workings lies on a claim held by the local community amenable to negotiate a deal with the Company. The vein is generally 1 metre wide with grades up to 12.6g/t gold but appear to average 4-8 g/t gold. Very little prospecting and sampling has been done on the vein between the underground workings. The Company plans to prospect this area to evaluate the vein and identify sections of higher grade gold values.
Silacayoapan
The 33,587 hectare Silocayopan property located in the western part of the state covers multiple known vein systems. In the Oaxaca state Geology and Mining Monograph, at least 4 vein systems are present, two of which are the Providencia and Soledad vein systems. Providencia is documented as a hydrothermal vein system with grades in the order of 16 g/t gold and 130 g/t silver. The Soledad vein system is documented as a hydrothermal vein system with copper grades in the order of 3%. The property has the benefit of a government sponsored 200 tonnes per day beneficiation plant in the area which, although not currently operational could be re-activated with proven mill feed from the district. Little is know of these vein systems. The Company is currently building a database for each vein system.
Nino Perdido
The 2,256 hectare Nino Perdido Property lies in a gold-silver-rich district southwest of the capital of Oaxaca and previously worked by the Spanish in historic times. According to the Oaxaca state Geology and Mining Monograph, gold grades in the area can reach between 6 and 13 g/t. Limited sampling by the Company has produced assays up to 80 g/t gold. The Company has very little information regarding mineralization on its property and is currently building is database there.
Tres Hermanas
The 3,710 hectare Tres Hermanas Property covers a silver-lead-zinc-bearing vein system that has historic underground workings on 5 levels along a 400 metre strike. Sampling underground show local values >500g/t silver. The Company has taken chip samples including 764.5 g/t silver and 10.4% lead across 1.5 metres. Regional soil sampling has indicated the vein system continues along strike in both directions. The vein system shows widths of 1-2 metres with a lower grade shell upwards of 15 metres wide. The Company continue to evaluate this project and work with the community.
On behalf of the Board of Directors of Arco Resources Corp
"Warren McIntyre"
Warren McIntyre
President and Chief Executive Officer
Arco Resources Corp
Paul Cowley, P.Geo., Chief Geologist for Arco Resources Corp., is the Qualified Person as defined in National Instrument 43-101, who has reviewed and approved the technical content of this news
Great Quest Completes $2.36 Million Agreement on Its Kenieba Concessions With Avion Gold Corporation
Last Update: 11/2/2009 9:03:13 AM
VANCOUVER, BRITISH COLUMBIA, Nov 02, 2009 (MARKETWIRE via COMTEX) -- Great Quest Metals Ltd. (GQ)(FRANKFURT: GQM) ('Great Quest') and Avion Gold Corporation (AVR) ("Avion") are pleased to announce that they have executed a definitive agreement in relation to their previously announced letter of intent (see Great Quest News Release dated April 21, 2009) to acquire 75% of Great Quest's interest in three mineral concessions located adjacent to the south and west sides of the Tabakoto property (see figure) (the "Option Agreement"). Great Quest previously spent approximately US$3.0 million in expenditures to explore the properties.
The Great Quest properties comprise the Kenieba (Sansanto), Kenieba Est and Comifa concessions totaling approximately 32 km2, which increases Avion's local property package by approximately 30%. The Kenieba concession hosts a 43-101 compliant inferred resource in the Djambaye 2 gold zone of 324,000 ounces (Carl Verley (P. Geo.), January 28, 2008 Great Quest news release). This equates to 2,574,000 tonnes grading 3.92 grams per tonne gold.
Commenting on the proposed acquisition, Avion's President and CEO, Mr. John Begeman stated, "As stated previously this disciplined acquisition represents an exciting opportunity for Avion to acquire nearby prospective gold projects that could provide additional feed for the Tabakoto mill and support Avion's stated growth and West African consolidation goals."
To acquire 75% of Great Quest's interest in the three mining concessions Avion is required to make cash payments of CDN$ 2,360,000 and complete work commitments of CDN$ 1,890,000 both over five years, subject to terms of the agreement. On signing of the Option Agreement Avion made a cash payment of CDN$ 350,000 and is required to complete at least CDN$ 150,000 of exploration expenditures in year 1. Great Quest's interest in the properties varies from 95% to 100% subject to a carried interest to the Government of Mali ranging between 10% and 20%.
"Avion plans to build upon Great Quest's work that has defined a series of northerly trending intrusion-hosted gold zones and gold mineralized, sediment- and intrusion-hosted cross-structures that are similar in character to those on the Avion concessions. A program of soil sampling and magnetic surveys will be carried out in early 2010 to provide a large scale property view prior to the selection of new and follow-up drill targets." comments Don Dudek, Vice President Exploration for Avion.
Willis W. Osborne, President and CEO of Great Quest, states "this is an excellent opportunity for the Company as it could enable production from the Great Quest concessions without the need to establish a mineral resource large enough to support a standalone mill and mining equipment. This could result in earlier production from the concessions then would normally be expected and the project will benefit from the Avion exploration success on its adjacent Tabakota concession". In Mali the Company will now focus on exploration on both its Bourdala gold concessions and its recently acquired Tin Hina phosphate concession.
ON BEHALF OF THE BOARD OF DIRECTORS OF GREAT QUEST METALS LTD.
Willis W. Osborne, President
The statements that are not historical facts and are forward-looking statements involving known and unknown risks and uncertainties could cause actual results to vary materially from the targeted results.
To view the map accompanying this news release, please click on the following link: http://media3.marketwire.com/docs/GQC.JPG
12g3-2(b) Exemption #82-3116
Standard & Poor's Listed
Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Great Quest Metals Ltd.
George Butterworth
Investor Relations
604-689-2882 or Toll Free: 877-325-3838
604-684-5854 (FAX)
info@greatquest.com
www.greatquest.com
SOURCE: Great Quest Metals Ltd.
GM
GRI
GGI
GRL
Gleichen is the one I was trying to remember. Odd name isn't it. Thanks!
I should have posted the link sooner. My bad.
Are you growing your mo?
http://ca.movember.com/
Hi Lone Clone
Do you recall a company recently picking up a nice gold property in Mexico from a major? I came across one but have now forgotten the name and symbol. I think the major was Teck but I'm not even sure of that.
Hey JW
Where you been? Did you get off at the wrong port and miss your flight home?
Gold Forecast: Jim Rogers 'rogered' by Roubini
2009-11-04 22:15:00
LONDON (Commodity Online): A gold forecast by global commodities guru Jim Rogers has turned controversial. Nouriel Roubini, the global economist who predicted the economic crisis, says the gold forecast by Jim Rogers that the yellow metal will double to $2,000 or more an ounce is "utter nonsense."
“Maybe, gold will touch $1,100 or so but $1,500 or $2,000 as predicted by Jim Rogers is nonsense,” Roubini told investors at the Inside Commodities Conference in New York. Gold rose to a historic record $1,096.20 today on the New York Mercantile Exchange’s Comex division on speculation that central banks and investors will purchase the metal to hedge against a declining dollar, said a Bloomberg report.
But Rogers countered Roubini by saying that the latter does not about the way in which gold prices have been moving up historically. “I think gold is go over $2000 some time in the bull market, but depending on what happens in the world it could go much, much higher,” Rogers said. “The old high, back in 1980 adjusted for inflation, would be over $2000 now, just to get back to the old high. So we’ll certainly get there some time in the next decade.”
Rogers, chairman of Singapore-based Rogers Holdings, said in an interview on Bloomberg Television: "The price of gold will double to at least $2,000 an ounce in the next decade."
Last month, Jim Rogers had said that commodities boom is not yet over and the bull market has several years to go. "No bullish view as fundamentals not supportive. But the precious metal will top $2000 in a decade.Gold will surpass its inflation-adjusted all-time high of more than $2,300 an ounce," the legendary commodities investor said.
Rogers also said: "Crude oil could touch $150 to $200 as known reserves decline and crude oil will run out in 15-20 years, " Unless something happens."
In his New York speech, Roubini asserted that asset prices have risen “too much, too soon, too fast.” He’s a New York University professor and chairman of New York research and advisory firm Roubini Global Economics.
The S&P-Goldman Sachs Commodity Spot Index is up 47 percent so far this year. Oil has risen 80 percent and gold is up 23 percent. The U.S. economy grew 3.5 percent in the third quarter after shrinking since the second quarter of 2008. Government incentives that spurred consumers to buy homes and cars boosted the recovery, the Commerce Department said on Oct. 29.
“It is very hard to justify oil going from $30 to above $80 based only on the fundamentals of supply and demand,” Roubini said. Prices are “in part” a bubble, Roubini added.
NXT
Anything's possible.
GAP {crap}
Yes, on Stockhouse as well. The share price is insane right now.
You bet. Are you in the States?
Maybe you guys might be interested in this microcap.
PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test
Last Update: 10/27/2009 8:30:49 AM
OTTAWA, ONTARIO, Oct 27, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") is pleased to announce highly positive results from the United States National Cancer Institute ("NCI") 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the single-dose study and provide definitive independent validation of GAP-107B8 as an active pharmaceutical ingredient against a wide range of cancers.
GAP-107B8 is a novel peptide protein kinase inhibitor that was designed to specifically target molecular signaling pathways in cancer cells. Targeted therapies are designed to target cancer cells while sparing surrounding normal, healthy, cells, thus causing less toxic effects than many standard chemotherapeutic agents currently in use.
Within a dose concentration range of 10 to 100 micromolar (u M), GAP-107B8 caused 100% growth inhibition (measured against cancer cell growth in untreated groups) in 51 of 56 cancer cell lines and caused at least 50% cancer cell death (measured against the number of cancer cells at the beginning of the test period) in 29 of 56 cancer cell lines.
The standard NCI test methodology generates three values that are used to measure the drug compound's activity against the cancer cell-line panel. These are: the GI50, the dose that causes an average 50% growth inhibition in the cell lines; the TGI, the dose that causes an average 100% growth inhibition in the cell lines; and the LC50, the dose that causes an average 50% cell death in the cell lines. For GAP-107B8, the GI50 was determined to be 23 u M, the TGI was 51 u M, and the LC50 was 89 u M. These data provide a very clear range of focus for all future studies.
These results provided a large amount of data, from the NCI testing which will be used by the Company to select specific cancer types and to determine an optimum dosing range for future animal studies and subsequent clinical trials. Based on these and prior results, the Company will be focusing its immediate development program on ovarian cancer and melanoma. The first of these animal studies is currently underway at the Ottawa Hospital Research Institute ("OHRI") in ovarian cancer. Further testing of GAP-107B8 on melanoma is about to commence under the guidance of Dr. Gary Schwartz at Memorial Sloan Kettering Cancer Center in New York. GAP-107B8 showed a strong effect in both melanoma and ovarian cancers in both single-dose and 5-dose testing at the NCI. In addition, the Company and NCI staff will meet in late November to discuss these results and ways in which the NCI may participate in various aspects of the development program for GAP-107B8.
The results across such a wide range of cancer cell lines, including a number which are known to be resistant to standard chemotherapy, indicate that GAP-107B8 has the potential to become a new cancer drug with less toxic side effects than common chemotherapeutic regimens.
Robert McInnis, President of the Company, stated "We are very pleased with the extent of activity in the NCI panel, as this activity against all cell lines provides a wide range of development opportunities for us, and provides us with additional support for a focus on ovarian cancer and melanoma. Our objective of the testing at the NCI - independent and verifiable validation of activity - has been fully realized. Over the past 12 months we have made significant progress in moving our lead drug to clinical trials: generating quality- controlled gram-scale production of the compound; achieving verifiable independent validation of compound activity at both the NCI and here in Ottawa at the OHRI; and programs underway in the area of bioassay development, understanding of signalling pathways involved, and continued testing programs at Memorial Sloan Kettering. This progress is very encouraging to me and to our team. Most importantly, results so far indicate a potential for new hope for the future of patients suffering from several types of cancer".
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
www.pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test
Last Update: 10/27/2009 8:30:49 AM
OTTAWA, ONTARIO, Oct 27, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") is pleased to announce highly positive results from the United States National Cancer Institute ("NCI") 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the single-dose study and provide definitive independent validation of GAP-107B8 as an active pharmaceutical ingredient against a wide range of cancers.
GAP-107B8 is a novel peptide protein kinase inhibitor that was designed to specifically target molecular signaling pathways in cancer cells. Targeted therapies are designed to target cancer cells while sparing surrounding normal, healthy, cells, thus causing less toxic effects than many standard chemotherapeutic agents currently in use.
Within a dose concentration range of 10 to 100 micromolar (u M), GAP-107B8 caused 100% growth inhibition (measured against cancer cell growth in untreated groups) in 51 of 56 cancer cell lines and caused at least 50% cancer cell death (measured against the number of cancer cells at the beginning of the test period) in 29 of 56 cancer cell lines.
The standard NCI test methodology generates three values that are used to measure the drug compound's activity against the cancer cell-line panel. These are: the GI50, the dose that causes an average 50% growth inhibition in the cell lines; the TGI, the dose that causes an average 100% growth inhibition in the cell lines; and the LC50, the dose that causes an average 50% cell death in the cell lines. For GAP-107B8, the GI50 was determined to be 23 u M, the TGI was 51 u M, and the LC50 was 89 u M. These data provide a very clear range of focus for all future studies.
These results provided a large amount of data, from the NCI testing which will be used by the Company to select specific cancer types and to determine an optimum dosing range for future animal studies and subsequent clinical trials. Based on these and prior results, the Company will be focusing its immediate development program on ovarian cancer and melanoma. The first of these animal studies is currently underway at the Ottawa Hospital Research Institute ("OHRI") in ovarian cancer. Further testing of GAP-107B8 on melanoma is about to commence under the guidance of Dr. Gary Schwartz at Memorial Sloan Kettering Cancer Center in New York. GAP-107B8 showed a strong effect in both melanoma and ovarian cancers in both single-dose and 5-dose testing at the NCI. In addition, the Company and NCI staff will meet in late November to discuss these results and ways in which the NCI may participate in various aspects of the development program for GAP-107B8.
The results across such a wide range of cancer cell lines, including a number which are known to be resistant to standard chemotherapy, indicate that GAP-107B8 has the potential to become a new cancer drug with less toxic side effects than common chemotherapeutic regimens.
Robert McInnis, President of the Company, stated "We are very pleased with the extent of activity in the NCI panel, as this activity against all cell lines provides a wide range of development opportunities for us, and provides us with additional support for a focus on ovarian cancer and melanoma. Our objective of the testing at the NCI - independent and verifiable validation of activity - has been fully realized. Over the past 12 months we have made significant progress in moving our lead drug to clinical trials: generating quality- controlled gram-scale production of the compound; achieving verifiable independent validation of compound activity at both the NCI and here in Ottawa at the OHRI; and programs underway in the area of bioassay development, understanding of signalling pathways involved, and continued testing programs at Memorial Sloan Kettering. This progress is very encouraging to me and to our team. Most importantly, results so far indicate a potential for new hope for the future of patients suffering from several types of cancer".
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
www.pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test
Last Update: 10/27/2009 8:30:49 AM
OTTAWA, ONTARIO, Oct 27, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") is pleased to announce highly positive results from the United States National Cancer Institute ("NCI") 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the single-dose study and provide definitive independent validation of GAP-107B8 as an active pharmaceutical ingredient against a wide range of cancers.
GAP-107B8 is a novel peptide protein kinase inhibitor that was designed to specifically target molecular signaling pathways in cancer cells. Targeted therapies are designed to target cancer cells while sparing surrounding normal, healthy, cells, thus causing less toxic effects than many standard chemotherapeutic agents currently in use.
Within a dose concentration range of 10 to 100 micromolar (u M), GAP-107B8 caused 100% growth inhibition (measured against cancer cell growth in untreated groups) in 51 of 56 cancer cell lines and caused at least 50% cancer cell death (measured against the number of cancer cells at the beginning of the test period) in 29 of 56 cancer cell lines.
The standard NCI test methodology generates three values that are used to measure the drug compound's activity against the cancer cell-line panel. These are: the GI50, the dose that causes an average 50% growth inhibition in the cell lines; the TGI, the dose that causes an average 100% growth inhibition in the cell lines; and the LC50, the dose that causes an average 50% cell death in the cell lines. For GAP-107B8, the GI50 was determined to be 23 u M, the TGI was 51 u M, and the LC50 was 89 u M. These data provide a very clear range of focus for all future studies.
These results provided a large amount of data, from the NCI testing which will be used by the Company to select specific cancer types and to determine an optimum dosing range for future animal studies and subsequent clinical trials. Based on these and prior results, the Company will be focusing its immediate development program on ovarian cancer and melanoma. The first of these animal studies is currently underway at the Ottawa Hospital Research Institute ("OHRI") in ovarian cancer. Further testing of GAP-107B8 on melanoma is about to commence under the guidance of Dr. Gary Schwartz at Memorial Sloan Kettering Cancer Center in New York. GAP-107B8 showed a strong effect in both melanoma and ovarian cancers in both single-dose and 5-dose testing at the NCI. In addition, the Company and NCI staff will meet in late November to discuss these results and ways in which the NCI may participate in various aspects of the development program for GAP-107B8.
The results across such a wide range of cancer cell lines, including a number which are known to be resistant to standard chemotherapy, indicate that GAP-107B8 has the potential to become a new cancer drug with less toxic side effects than common chemotherapeutic regimens.
Robert McInnis, President of the Company, stated "We are very pleased with the extent of activity in the NCI panel, as this activity against all cell lines provides a wide range of development opportunities for us, and provides us with additional support for a focus on ovarian cancer and melanoma. Our objective of the testing at the NCI - independent and verifiable validation of activity - has been fully realized. Over the past 12 months we have made significant progress in moving our lead drug to clinical trials: generating quality- controlled gram-scale production of the compound; achieving verifiable independent validation of compound activity at both the NCI and here in Ottawa at the OHRI; and programs underway in the area of bioassay development, understanding of signalling pathways involved, and continued testing programs at Memorial Sloan Kettering. This progress is very encouraging to me and to our team. Most importantly, results so far indicate a potential for new hope for the future of patients suffering from several types of cancer".
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
www.pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
PharmaGap Reports That GAP-107B8 Showed Strong and Consistent Anti-Cancer Activity in a Wide Range of Cancers in NCI Test
Last Update: 10/27/2009 8:30:49 AM
OTTAWA, ONTARIO, Oct 27, 2009 (Marketwire via COMTEX) -- PharmaGap Inc. (GAP)(PHRG.F) ("PharmaGap" or "the Company") is pleased to announce highly positive results from the United States National Cancer Institute ("NCI") 5-dose in vitro anti-cancer screen of PharmaGap drug GAP-107B8. These results confirm and extend results announced in August from the single-dose study and provide definitive independent validation of GAP-107B8 as an active pharmaceutical ingredient against a wide range of cancers.
GAP-107B8 is a novel peptide protein kinase inhibitor that was designed to specifically target molecular signaling pathways in cancer cells. Targeted therapies are designed to target cancer cells while sparing surrounding normal, healthy, cells, thus causing less toxic effects than many standard chemotherapeutic agents currently in use.
Within a dose concentration range of 10 to 100 micromolar (u M), GAP-107B8 caused 100% growth inhibition (measured against cancer cell growth in untreated groups) in 51 of 56 cancer cell lines and caused at least 50% cancer cell death (measured against the number of cancer cells at the beginning of the test period) in 29 of 56 cancer cell lines.
The standard NCI test methodology generates three values that are used to measure the drug compound's activity against the cancer cell-line panel. These are: the GI50, the dose that causes an average 50% growth inhibition in the cell lines; the TGI, the dose that causes an average 100% growth inhibition in the cell lines; and the LC50, the dose that causes an average 50% cell death in the cell lines. For GAP-107B8, the GI50 was determined to be 23 u M, the TGI was 51 u M, and the LC50 was 89 u M. These data provide a very clear range of focus for all future studies.
These results provided a large amount of data, from the NCI testing which will be used by the Company to select specific cancer types and to determine an optimum dosing range for future animal studies and subsequent clinical trials. Based on these and prior results, the Company will be focusing its immediate development program on ovarian cancer and melanoma. The first of these animal studies is currently underway at the Ottawa Hospital Research Institute ("OHRI") in ovarian cancer. Further testing of GAP-107B8 on melanoma is about to commence under the guidance of Dr. Gary Schwartz at Memorial Sloan Kettering Cancer Center in New York. GAP-107B8 showed a strong effect in both melanoma and ovarian cancers in both single-dose and 5-dose testing at the NCI. In addition, the Company and NCI staff will meet in late November to discuss these results and ways in which the NCI may participate in various aspects of the development program for GAP-107B8.
The results across such a wide range of cancer cell lines, including a number which are known to be resistant to standard chemotherapy, indicate that GAP-107B8 has the potential to become a new cancer drug with less toxic side effects than common chemotherapeutic regimens.
Robert McInnis, President of the Company, stated "We are very pleased with the extent of activity in the NCI panel, as this activity against all cell lines provides a wide range of development opportunities for us, and provides us with additional support for a focus on ovarian cancer and melanoma. Our objective of the testing at the NCI - independent and verifiable validation of activity - has been fully realized. Over the past 12 months we have made significant progress in moving our lead drug to clinical trials: generating quality- controlled gram-scale production of the compound; achieving verifiable independent validation of compound activity at both the NCI and here in Ottawa at the OHRI; and programs underway in the area of bioassay development, understanding of signalling pathways involved, and continued testing programs at Memorial Sloan Kettering. This progress is very encouraging to me and to our team. Most importantly, results so far indicate a potential for new hope for the future of patients suffering from several types of cancer".
About The National Cancer Institute
The National Cancer Institute (NCI), located in Bethesda, MD is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI has a mandate to select and screen novel drug compounds that could potentially make a material difference in the "war against cancer". Selection to the NCI screening program is through a competitive application process. Details on the NCI's compound screening program can be found at http://dtp.nci.nih.gov/ . More general information on the NCI is found at www.cancer.gov .
About PharmaGap Inc.
PharmaGap Inc. (GAP)(PHRG.F), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is a novel peptide drug designed to inhibit the activity of protein kinase C (PKC), a cell signalling enzyme implicated in certain types and stages of cancer. Independent peer-reviewed research has demonstrated that over-expression of PKC plays a role in the development of many cancer types. For more information please visit www.pharmagap.com .
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
SOURCE: PharmaGap Inc.
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-9551
bmcinnis@pharmagap.com
www.pharmagap.com
Copyright (C) 2009 Marketwire. All rights reserved.
GAP waking up here. NCI 5-dose news may be coming.